| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mehdi Farokhnia, Mikela B Sheskier, Mary R Lee, April N Le, Erick Singley, Sofia Bouhlal, Timmy Ton, Zhen Zhao, Lorenzo Leggi. Neuroendocrine response to GABA-B receptor agonism in alcohol-dependent individuals: Results from a combined outpatient and human laboratory experiment. Neuropharmacology. vol 137. 2019-02-20. PMID:29665351. |
blood samples were collected, and the following neuroendocrine markers were measured: ghrelin, leptin, amylin, glucagon-like peptide-1 (glp-1), insulin, prolactin, thyroid-stimulating hormone, growth hormone, cortisol, and adrenocorticotropic hormone (acth). |
2019-02-20 |
2023-08-13 |
human |
| Mehdi Farokhnia, Mikela B Sheskier, Mary R Lee, April N Le, Erick Singley, Sofia Bouhlal, Timmy Ton, Zhen Zhao, Lorenzo Leggi. Neuroendocrine response to GABA-B receptor agonism in alcohol-dependent individuals: Results from a combined outpatient and human laboratory experiment. Neuropharmacology. vol 137. 2019-02-20. PMID:29665351. |
significant drug × time-point interaction effects for amylin (p = 0.001) and insulin (p = 0.03), and trend-level interaction effects for glp-1 (p = 0.06) and acth (p = 0.10) were found during the laboratory experiment. |
2019-02-20 |
2023-08-13 |
human |
| Sudha S Shankar, R Ravi Shankar, Lori A Mixson, Deborah L Miller, Helmut O Steinberg, Chan R Beals, David E Kelle. Insulin secretory effect of sitagliptin: assessment with a hyperglycemic clamp combined with a meal challenge. American journal of physiology. Endocrinology and metabolism. vol 314. issue 4. 2019-02-18. PMID:29138226. |
there was an associated significant treatment-based increase in circulating insulin, as well as active levels of glp-1. |
2019-02-18 |
2023-08-13 |
human |
| M Güemes, S A Rahman, P Shah, K Hussai. Enteroinsular hormones in two siblings with Donohue syndrome and complete leptin deficiency. Pediatric diabetes. vol 19. issue 4. 2019-02-12. PMID:29226618. |
two siblings with genetically confirmed ds and extremely low weight underwent a mixed meal (mm) test where pancreatic hormones insulin, c-peptide, glucagon, active amylin, pancreatic polypeptide (pp) as well as gut hormones active glucagon-like peptide 1 (glp-1), glucose-dependent insulinotropic peptide (gip), ghrelin, peptide yy (pyy) and leptin were analyzed using a multiplex assay. |
2019-02-12 |
2023-08-13 |
human |
| Maria Ida Maiorino, Paolo Chiodini, Giuseppe Bellastella, Lorenzo Scappaticcio, Miriam Longo, Katherine Esposito, Dario Giuglian. Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes, obesity & metabolism. vol 20. issue 9. 2019-02-05. PMID:29732679. |
free and fixed-ratio combinations of basal insulin and glp-1 receptor agonists versus basal insulin intensification in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. |
2019-02-05 |
2023-08-13 |
Not clear |
| A J Scheen, C Mathie. [Basal insulin degludec - liraglutide fixed ratio combination (Xultophy®)]. Revue medicale de Liege. vol 73. issue 10. 2019-01-31. PMID:30335259. |
xultophy® (ideglira) is a fixed ratio combination of basal insulin degludec and glucagon-like peptide-1 (glp-1) receptor agonist liraglutide. |
2019-01-31 |
2023-08-13 |
Not clear |
| Najlaa M Al-Mana, M Denise Robertso. Acute Effect of Resistant Starch on Food Intake, Appetite and Satiety in Overweight/Obese Males. Nutrients. vol 10. issue 12. 2019-01-31. PMID:30558330. |
postprandial qualitative appetite, glucose, insulin, and glp-1 were measured every 30 min for 7 h. energy intake values from an |
2019-01-31 |
2023-08-13 |
human |
| Uchenna Anyanwagu, Jil Mamza, Richard Donnelly, Iskandar Idri. Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study. American heart journal. vol 196. 2019-01-30. PMID:29421011. |
combining a glp-1 receptor agonist (glp-1ra) with insulin is often an effective treatment strategy for overweight patients with type 2 diabetes (t2d), but little is known about the longer-term effects on cardiovascular and mortality outcomes in routine clinical practice in the united kingdom. |
2019-01-30 |
2023-08-13 |
Not clear |
| Qiuyu Wang, Chunlin Zhao, Lili Jin, Hanyu Zhang, Qifan Miao, Hongsheng Liu, Dianbao Zhan. AWRK6, a Novel GLP-1 Receptor Agonist, Attenuates Diabetes by Stimulating Insulin Secretion. International journal of molecular sciences. vol 19. issue 10. 2019-01-22. PMID:30301245. |
awrk6, a novel glp-1 receptor agonist, attenuates diabetes by stimulating insulin secretion. |
2019-01-22 |
2023-08-13 |
mouse |
| Dilan Athauda, Thomas Foltyni. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease. Neuropharmacology. vol 136. issue Pt B. 2019-01-17. PMID:28927992. |
we review the relationship between insulin resistance and parkinson's disease, the implications on pathogenesis and the efforts to reposition glp-1 agonists as potential treatments for parkinson's disease and give an overview of the pre-clinical and clinical data supporting the use of exenatide in parkinson's disease with a discussion regarding possible mechanisms of action. |
2019-01-17 |
2023-08-13 |
human |
| Christian Hölsche. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models. Neuropharmacology. vol 136. issue Pt B. 2019-01-17. PMID:29402504. |
glp-1 and gip are growth factors that re-sensitise insulin and glp-1 mimetics are used in the clinic to treat diabetes. |
2019-01-17 |
2023-08-13 |
Not clear |
| Sourav De, Subhasis Banerjee, S K Ashok Kumar, Priyankar Pair. Critical Role of Dipeptidyl Peptidase IV: A Therapeutic Target for Diabetes and Cancer. Mini reviews in medicinal chemistry. vol 19. issue 2. 2019-01-16. PMID:29692250. |
it is a protease enzyme which inactivates incretin hormones i.e., glucagonlike peptide 1 (glp-1) and glucose-dependent insulin tropic polypeptide (gip). |
2019-01-16 |
2023-08-13 |
Not clear |
| Ying Li, Tao Cui, Xiaodong Kong, Xiulin Yi, Dexin Kong, Jianning Zhang, Changxiao Liu, Min Gon. Nanoparticles induced by embedding self-assembling cassette into glucagon-like peptide 1 for improving in vivo stability. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 32. issue 6. 2019-01-15. PMID:29401602. |
both cadyglp1e and cadyglp1m retained glucoregulatory activity after insulin stimulation and were potent drug candidates for long-acting glp-1 derivatives to treat type 2 diabetes mellitus. |
2019-01-15 |
2023-08-13 |
Not clear |
| S Lanzinger, S M Schmid, R Welp, A Zimmermann, P Fasching, S Wagner, R W Hol. Clinical inertia among patients with type 2 diabetes mellitus treated with DPP-4i and/or SGLT-2i. Diabetes research and clinical practice. vol 146. 2019-01-08. PMID:30367902. |
if newer oral anti-diabetic drugs (noads) such as dipeptidyl peptidase-4 inhibitors (dpp-4i) and sodium/glucose cotransporter 2 inhibitors (sglt-2i) do not achieve metabolic control, injectable therapy like insulin or glucagon-like peptide 1 (glp-1) receptor agonists are required. |
2019-01-08 |
2023-08-13 |
Not clear |
| Nino Jejelava, Sharon Kaufman, Jean-Philippe Krieger, Marcella Martins Terra, Wolfgang Langhans, Myrtha Arnol. Intestinal lymph as a readout of meal-induced GLP-1 release in an unrestrained rat model. American journal of physiology. Regulatory, integrative and comparative physiology. vol 314. issue 5. 2019-01-07. PMID:29341824. |
we here assessed how mesenteric lymph duct (mld) lymph levels of glucagon-like peptide (glp-1), insulin, and metabolites [glucose and triglycerides (tg)] evolve after isocaloric high- and low-fat diet (hfd and lfd) meals and how they compare with hepatic portal vein (hpv) plasma levels. |
2019-01-07 |
2023-08-13 |
rat |
| Andrea Tura, Roberto Bizzotto, Yuchiro Yamada, Yutaka Seino, Giovanni Pacini, Bo Ahré. Increased insulin clearance in mice with double deletion of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors. American journal of physiology. Regulatory, integrative and comparative physiology. vol 314. issue 5. 2019-01-07. PMID:29351421. |
to establish whether incretin hormones affect insulin clearance, the aim of this study was to assess insulin clearance in mice with genetic deletion of receptors for both glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip), so called double incretin receptor knockout mice (dirko). |
2019-01-07 |
2023-08-13 |
mouse |
| David M Williams, Natasha Shrikrishnapalasuriyar, Waheeba Syed, Win L Yin, Richard Chudleigh, Stephen C Bain, David E Price, Jeffrey W Stephen. Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic. Diabetes & metabolic syndrome. vol 12. issue 6. 2019-01-07. PMID:30006093. |
xultophy is the first fixed co-formulation pen containing insulin degludec and the glucagon-like peptide-1 (glp-1) analogue liraglutide, authorized for type 2 diabetes patients since 2014. |
2019-01-07 |
2023-08-13 |
Not clear |
| Christine Poitou, Elodie Bouaziz-Amar, Laurent Genser, Jean-Michel Oppert, Jean-Marc Lacorte, Johanne Le Beye. Fasting levels of glicentin are higher in Roux-en-Y gastric bypass patients exhibiting postprandial hypoglycemia during a meal test. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. vol 14. issue 7. 2019-01-02. PMID:29703503. |
after rygb, exaggerated secretion of glucagon-like peptide-1 (glp-1) and insulin could lead to pph, but other proglucagon-derived peptides, including glicentin and glucagon, could also contribute to this phenomenon. |
2019-01-02 |
2023-08-13 |
Not clear |
| L Kolatorova, M Sramkova, J Vitku, J Vcelak, O Lischkova, L Starka, M Duskov. Parabens and their relation to obesity. Physiological research. vol 67. issue Suppl 3. 2018-12-31. PMID:30484673. |
basal anthropometric measures, levels of parabens (methylparaben, ethylparaben and propylparaben), adipokines (adiponectin, adipsin, leptin, resistin and visfatin) and hormones affecting energy balance and metabolic health (c-peptide, ghreline, gip, glp-1, glucagon, insulin, pai-1) were measured. |
2018-12-31 |
2023-08-13 |
Not clear |
| Emilie Normand, Anita Franco, Alain Moreau, Valérie Marci. Dipeptidyl Peptidase-4 and Adolescent Idiopathic Scoliosis: Expression in Osteoblasts. Scientific reports. vol 7. issue 1. 2018-12-27. PMID:28600546. |
in circulation, dipeptidyl peptidase-4 (dpp-4) inactivates glucagon-like peptide-1 (glp-1), an incretin that promotes insulin secretion and sensitivity. |
2018-12-27 |
2023-08-13 |
human |